BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeut

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues othe

On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue

BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Confere

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) annou

Amundi lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 37.8% during the

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Tra

BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conf

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMR

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transc

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, r

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial f

Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare C

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Over

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline cata

Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN

Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and rai

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 poi

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of A

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pha

BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting Bi

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into binding terms wi

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMar

Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL,

Bank of New York Mellon Corp bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: B

ADAR1 Capital Management LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) dur

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease p

BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 mil

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and pri

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) wi

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definiti

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Over

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight a

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Ov

Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outper

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the

Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and rais

The sNDA submission was supported by substantial long-term safety and efficacy data from three ongoi

RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perfo

Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strengt

Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page